Healthcare Services

Low-Grade Glioma Market Forecast Covering Industry Demand And Market Evolution

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Low-Grade Glioma Market Through 2030?

The low-grade glioma market has experienced substantial expansion in recent times. It is projected to increase from $1.47 billion in 2025 to $1.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. Historically, this growth can be ascribed to several factors, including developments in neuroimaging technologies, enhanced survival rates for low-grade glioma patients, a rise in neurosurgical interventions, increased public knowledge regarding brain tumor symptoms, and the proliferation of oncology treatment facilities.

The low-grade glioma market is anticipated to exhibit substantial growth in the upcoming years, expanding to $1.94 billion by 2030, with a compound annual growth rate (CAGR) of 5.6%. This projected growth throughout the forecast period can be attributed to an increased emphasis on molecular tumor profiling, rising investments in targeted oncology drugs, a growing demand for less aggressive treatment alternatives, broadening access to specialized neuro-oncology care, and ongoing clinical trials for innovative therapies. Key trends during the forecast period involve a heightened focus on early diagnosis and consistent monitoring, increasing adoption of targeted drug therapies, a growing preference for multimodal treatment approaches, the expansion of personalized treatment planning, and the emergence of enhanced long-term disease management strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

What Primary Factors Are Fueling The Expansion Of The Low-Grade Glioma Market?

The anticipated increase in brain tumor occurrences is set to drive expansion within the low-grade glioma market in the future. Brain tumors are characterized by anomalous cell proliferation within the brain or adjacent regions, potentially being either non-cancerous or cancerous. This surge in brain tumor cases stems from contributors like heightened radiation exposure, environmental contaminants, genetic susceptibility, and the natural aging process. Low-grade glioma treatment benefits brain tumor patients through the application of sophisticated diagnostic methods and specific therapies, including surgery, radiation, and chemotherapy. These interventions are vital for decelerating tumor advancement, safeguarding neurological capabilities, and enhancing patient prognosis, thereby emphasizing the critical importance of prompt identification and tailored care for handling other brain tumors exhibiting comparable growth profiles. As an illustration, in October 2025, figures from Cancer Australia, a government body based in Australia, indicated that in 2023, Australia registered 1,597 brain cancer fatalities (comprising 956 men and 641 women). Projections for 2025 suggest a modest increase to 1,639 deaths (including 979 men and 660 women). The projected likelihood of succumbing to brain cancer by age 85 in 2025 stands at 1 in 195 (0.51%), with males facing a higher risk of 1 in 165 (0.61%) and females a lower risk of 1 in 240 (0.42%). Consequently, the increasing occurrence of brain tumors is a primary impetus for the expansion of the low-grade glioma market.

How Does Segment Analysis Break Down The Low-Grade Glioma Market Structure?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

What Trends Are Affecting The Growth Of The Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted treatment approaches, including genetic alteration drugs, to gain a competitive advantage and enhance the care of children with low-grade glioma. Genetic alteration drugs represent targeted therapies engineered to modify or inhibit specific genetic mutations or cellular abnormalities, thereby assisting in the treatment of diseases such as cancer by blocking the pathways responsible for uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after securing accelerated FDA approval. This targeted therapy is intended for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) that carries BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients who have had limited prior treatment options.

Who Are The Leading Firms Participating In The Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Access The Complete Low-Grade Glioma Market Report:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which Region Accounts For The Highest Share Of The Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Low-Grade Glioma Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795